Pharmaceuticals, Biotechnology, Renewable Energy, Diagnostics, Bioagriculture, Cosmeceuticals, Environmental, CPG

Dr. Benjamin Reed has 10+ years of expertise in bridging company strategy to executable projects within the microbial and fermentation industries. He worked at Novonesis (previously Novozymes) for 7 years, where he enabled strategic product launches for Animal Health, BioAgriculture, Bioenergy, Human Health, Wastewater, and Household Care. At Novonesis, he led the invention of a method that predicts bioethanol yeast performance at production volumes from a <100ml testing environment. Following Novonesis, Ben joined the renewable energy startup Cemvita as Director of Business Operations and Project Management. He led the establishment of their stage-gate and PMO process, which contributed to the successful spin-off and funding of affiliates Gold Hydrogen and Endolith. Later, Ben joined the alternative protein CPG company Meati Inc. as Director of Program Management. There, he led an evaluation of their product innovation strategy, mobilized a new company structure and PMO, and enabled the launch of a two-ingredient alternative protein product.

Dr. Reed has set up or revitalized product innovation pipelines for a range of B2B and CPG companies. He has experience with TEA, LCA, and regulatory/quality evaluations for microbial manufacturing. His expertise spans pharmaceuticals, carbon capture, environmental remediation, biofuels, precision fermentation, and enzyme development. He earned a PhD in Pharmacology from the University of Washington under Dr. Richard Gardner, and conducted post-doctoral research at Duke University under Dr. Mike Lynch as part of DMC Biotechnologies. Contact Dr. Reed.